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Abstract— Parkinson disease (PD) characteristic motor dysfunctions are tremors, stiffness, bradykinesia and gait
disorders.
We use an experimental adult male rat model of hemiparkinsonism and investigate chronic estrogen administration
effects in the functionality of the nigrostriatal dopaminergic system.
Forelimb akinesia in rats is analogous to limb akinesia and gait problems seen in patients with PD. We have
developed a software to test adjusting steps, stepping time, step length and initiation time. The implementation
tracks each animal forelimb movement and measures those parameters. It performs statistical analysis and
presents data in bar charts or Excel sheets.
The software was validated by correlating manual and automated adjusting steps.
Estrogen treated animals exhibit a higher compensatory mechanism to motor dysfunction, improving the number
of adjusting steps and showing less bradykinesia. Also, there is a beneficial effect of estrogen related to a higher
average energy that could be enhancing stepping time and forelimb movement magnitude.
In conclusion, this software development and implementation is a worthy tool to in vivo infer on forelimb akinesia.
By applying it, we obtain a new sensitive approach in the effect of estrogen as a neuroprotective drug in PD as it
restores balance, mobility, speed and also diminishes bradykinesia.
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Resumen— Las disfunciones motoras caracterı́sticas de la enfermedad de Parkinson (EP) son temblores, rigidez,
bradicinesia y trastornos de la marcha. Utilizamos un modelo experimental de hemiparkinsonismo en ratas macho
adultas e investigamos los efectos de la administración crónica de estrógeno en la funcionalidad del sistema
dopaminérgico nigroestriatal. La acinesia en las patas delanteras de las ratas es análoga a la acinesia de las
extremidades y problemas de marcha observados en pacientes con EP. Hemos desarrollado un software para medir
los pasos de los animales, el tiempo de paso, la longitud del paso y el tiempo de inicio. La implementación hace
un seguimiento de cada movimiento animal de la extremidad anterior y mide esos parámetros. Realiza análisis
estadı́sticos y presenta datos en gráficos de barras o hojas de Excel.
El software se validó correlacionando los pasos por conteo manual y automático. Los animales tratados con
estrógeno exhiben un mecanismo compensatorio más alto ante la disfunción motora, mejorando el número de pasos
y mostrando menos bradicinesia. Además, hay un efecto beneficioso del estrógeno relacionado con una energı́a
promedio más alta que podrı́a mejorar el tiempo de avance y la magnitud del movimiento de las extremidades
anteriores. En conclusión, este desarrollo e implementación de software es una valiosa herramienta para textit in
vivo inferir sobre la acinesia de la extremidad anterior. Al aplicarlo, obtenemos un nuevo enfoque sensible en el
efecto del estrógeno como fármaco neuroprotector en la EP, ya que restaura el equilibrio, la movilidad, la velocidad
y también disminuye la bradicinesia.
Palabras clave— Enfermedad de Parkinson, Akinesia, 6 hidroxidopamine, modelo animal, monitoreo por video ,
rastreo de trayectoria.
I. INTRODUCTION
Parkinson Disease (PD) is relatively common and serious
impairment of health in developing countries all around
the world, which affects 1% of the population over 55
years, with a mean onset of 60 years [1]. The disease is
degenerative and progressive, and it is expected to become
a serious public health problem [2]. The brains of patients
suffering from PD show a profound deficit in dopamine
levels, because of the loss of neurons in the nigrostriatal
pathway. The continuous neuronal degeneration in substantia
nigra pars compacta and the dopaminergic deficit in corpus
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striatum, generate functional modifications on the basal
ganglia system with the consequent characteristic motor
dysfunctions such as tremors, stiffness, bradykinesia and gait
disorders [3].
It is known that neurosteroids have functional beneficial
properties in the Central Nervous System (CNS). Some of
them are protection against deleterious agents, enhancement
of cognitive abilities and neurogenesis promotion in human
and animal models of neurodegenerative diseases. It has also
been described that these molecules bind to specific sites of
the cell membrane in regions of the CNS; other than those
involved in reproductive functions [4]. PD affects men more
than women and there are evidences supporting female sex-
ual steroids’ neuroprotective properties. Furthermore several
neuroprotective and neuroregulatory effects of estrogen have
been described for PD [5] [6].
Considering that several reports inform unilateral 6-OHDA
lesioned rats as a suitable animal model for behavioral and
biochemical evaluation of PD [7] [8], we use an experi-
mental male rat model of hemiparkinsonism induced by 6-
OHDA in which we investigate the effects of estrogen in
the functionality of the nigrostriatal dopaminergic system.
Particularly, for this work, we have developed a bioinfor-
matic software for forelimb akinesia, in which we assess
different parameters (adjusting steps, stepping time, step
length and initiation time) analogous to limb akinesia and
gait problems seen in patients with PD [9]. By using this
computerized technique we’ll be able to early, with high
sensitivity and in vivo infer about motor parameters related
to forelimb akinesia. The software implementation will
contribute on describing nigrostriatal dopamine dysfunction
and revealing estrogen neuroprotective effects in the animal
model of PD.
II. MATERIALS AND METHODS
A. Animals
We used male Sprague Dawley rats from our breeding
colony. They were 60 days old at the beginning of the study,
and their weight was 280-340 g. Experimental subjects were
housed under controlled conditions of temperature (22 ± 3
 C) and lighting (12 hour cycle beginning at 7:00 a.m.),
with food and water made available ad libitum. Animals
were kept and handled according to the Guide for the Care
and Use of Laboratory Animals of the National Research
Council (National Academies, U.S.A, 8th edition, 2011). All
efforts were made to minimize animal suffering.
B. Surgical procedures
On postnatal day 60, forty animals were anesthetized
with an intraperitoneal injection of ketamine (100 mg/kg)
and xylazine (20 mg/kg) and placed into a stereotaxic
frame (David Kopf, USA). The neurotoxin, 6-OHDA was
dissolved at a concentration of 2 µg/µl saline in 0.1%
ascorbic acid. In order to achieve unilateral lesions of the
nigrostriatal system, 20 rats received 6-OHDA injections and
other 20 got vehicle (V) into the left corpus striatum. The
lesion was performed by injecting the neurotoxic or vehicle
with a Hamilton syringe at the following coordinates: AP:
+1.2 mm; ML: +2.5 mm; DV: -5.0 mm; TB at 0 mm. The
injection was conducted at a rate of 0.5 µl/min and the
needle was left in place for another 5 min before it was
slowly drawn back. After surgery, when animals were fully
recovered, they were taken to a room where they rested for
seven days. From PND 67 to 77, 20 rats received chronic
treatment with 17 -Estradiol (E= 0.1 µg/kg/day s.c) and 20
got oil (O) as vehicle. Groups were conformed as HP+E
(6-OHDA lesion, E treatment, n=10); HP (6-OHDA lesion,
O treatment, n=10); E (V lesion, E treatment, n=10); C (V
lesion, O treatment, n=10).
C. Forelimb akinesia test
The procedure was similar to the one described by Olsson
[9] with some modifications. The test was performed on a
smooth-surfaced wooden table with a length of 0.9 m (Fig.
1). Behavioral records were all made during daytime by an
observer blinded to the animal condition.
Fig. 1. Animal handling and experimental grip length.
Procedures followed the next outline (Fig. 2); for three
days (PND 114,115 and 116), rats were handled by an
experimenter and trained for the testing sequence described
below. These scores were not recorded. On PND 117, one
hour before the test all animals were taken to the behavioral
testing room to get used to the environment. The test was
video recorded for subsequent software analysis.
Fig. 2. Experimental timeline.
• Testing sequence.
As it is shown in Fig. 1, the rat was held by the
experimenter with one hand fixing the hindlimb and
slightly raising the hind part above the surface, the
other hand fixed the forelimb not to be monitored.
Then it was moved slowly sideways (0.9 m for 5s)
by the experimenter. The testing sequence was right
paw forehand and backhand adjusting steps (RP-F,
RP-B), followed by left paw forehand and backhand
directions (LP-F, LP-B).
The following parameters were counted for both paws
in both directions and the sequence was repeated three
times.
-Initial time [s]: measured until the rat made the first
step.
-Stepping time [s]: measured from first step until the
rat reaches the end of the trajectory.
-The number of adjusting steps was counted for both
paws in the backhand and forehand directions of
movement.
-Step length [px]: tested as the magnitude between
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each adjusting step.
• Statistical analysis.
For software validation Pearson correlation coefficient
between manual and automated adjusting steps was
calculated.
Statistical evaluation of estrogen effects on forelimb
akinesia test depends on the population’s nature. For
comparisons between the four groups, if data distribu-
tion is parametric, results are expressed as means ±
SD; data was analyzed with Anova One-Way followed
by Tukey’s Honest Significant Difference Test. If data
distribution follows a non-parametric distribution, re-
sults are expressed as medians ± SD and shown as
medians. In this case, Kruskal Wallis test followed by
Dunn post hoc test was applied.
Statistical significance level was set at p< 0.05.
D. Software implementation
The first stage of this procedure (Fig. 3) consists in
conditioning the behavioral testing room according to
set parameters. It is an obligation to configure light and
temperature according to standard conditions to avoid
animals stress. Also, camera speed and resolution must be
determined at the highest level available in [frames/s] and
pixels, respectively. For this purpose, camera is set in 29
frames/s and 720x480 resolution.
Fig. 3. Software implementation process.
After this pre-conditioning, animal’s sequence of testing
is performed and video recorded. To track each animal
forelimb movement we use Kinovea 0.8.15 [10], a biome-
chanical analysis video software. These results ase exported
from the software as a MS-XML file.
For data processing we developed a software in language
Python 2.7.9 [11]. This program consists in measuring
stepping test parameters, making statistical analysis and
presenting results. To begin, it requires the location of the
files exported from Kinovea (this data has to be converted
into excel files, XLSX). Each testing group is organized
as a file that contains all the animals trajectories. This
files must be ordered progressively (Fig. 4). The software
asks the user to indicate the number of groups and the
amount of animals per group. The user can label each
group according to the experimental condition. After this,
forelimb akinesia parameters are automatically calculated.
This implementation has a module to perform statistical
analysis which embodies a set of assumptions concerning on
the population distribution and the number of groups tested;
and graphic user interface that presents data in barcharts or
Excel sheets.
Fig. 4. Kinovea’s output. Each file represents the different groups tested
(above), inside of it there is an excel sheet per animal analyzed as it is
shown below.
III. RESULTS
In order to validate the software we use adjusting steps, as
it is the only one parameter that could be compared between
manual and automatic measurements. Fig. 5 displays the
presence of correlation in values corresponding to this
parameter of the testing sequence for all groups, from direct
observations and automated software.
Fig. 5. Results of manual vs automated correlations for each group tested.
As it is shown in Table I, there is a high correlation
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between manual and automated values. For all groups, Pear-
son’s coefficient was almost near 1.00 with p-value<0.01.
This result represents a strong positive linear relationship
among both calculations.
TABLE I
PEARSON’S CORRELATION COEFFICIENTS FOR ALL GROUPS.
Group Correlation coefficients p-value Level of sig-
nificance
HP+E 0.992 0.008 **
HP 0.998 0.002 **
E 0.979 0.008 **
C 0.987 0.013 **
A. Estrogen effects on forelimb akinesia test
• Adjusting steps
Fig. 6 shows a considerably large difference between
C and HP+E with HP and E groups according to the
sequence of testing for adjusting steps performance.
We could see that HP animals displayed a forelimb
imbalance pattern and the most affected movement in
the sequence of testing was RP-F, the value of this
parameter was (8.1±1.09).
For HP+E group, the number of adjusting steps in
the direction RP-F (7.6±1.0) was significantly different
(p value<0.001) to RP-B (4.8±1.55) and also to LP-
B (6.1±1.92).
E group also exhibited unequal movements with a sim-
ilar pattern to HP. In this case, LP-F value (8.67±1.18)
was the biggest value in the testing sequence.
Finally, RP-B value (5.4±1.83) in C group presented
was significantly different from RP-F (7.9±1.75) and
LP-F (8.85±2.04).
Fig. 6. Adjusting steps according to the testing sequence for all groups
tested.
• Initial time
The duration until the rat made the first step was
more than three times larger for lesioned animals. RP-F
initial time in HP group (0.36±2.78 s) was three times
greater than that same parameter for HP+E (0.2±0.39
s), C (0.22±0.33 s) and E (0.20±0.16 s) group where
this parameter never exceeded 1s.
What is more HP group presented differences among
the testing sequence; the highest value was for RP-
F, followed by RP-B (0.24±1.94 s), then by LP-B
(0.22±1.85 s) and finally LP-F (0.19±2.34 s).
Fig. 7. Initial time corresponding to the testing sequence for all groups
tested.
• Stepping time
The only group that presented significantly differences
was HP. In its testing sequence, RP-F (2.59±2.20 s)
forelimb movement is the highest, followed by LP-F
(2.55±1.70 s). For both paws in backhand direction
this parameter was considerably less, (2.28±1.30 s) for
LP-B and (2.17±1.41 s) for RP-B respectively.
The evaluation of this value in the other three groups
yields no difference in any testing sequence.
Fig. 8. Stepping time parameter related to the testing sequence for all
groups tested.
• Step length
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There is no difference (in any group or testing se-
quence) of the magnitude between each adjusting step.
As it is shown in Fig. 9 there is a tendency for RP-
B to be the largest value in HP (41.66±57.26 px),
C (41.05±40.22 px) and E group (63.61±26.02 px);
although this imbalance is not seen in HP+E group.
The equivalence to interpret this results in centimeters
is: 1px=0.23 cm.
Fig. 9. Step length according to the testing sequence for all groups tested.
IV. CONCLUSION
There are less differences between the number of adjust-
ing steps in HP+E compared to HP group. With this result
we infer that the HP+E animals are able to improve the
number of steps performed.
This kind of neurotoxic hemilateral lesion, provides a clear
motor dysfunction behavioral response in RP-F direction of
movement, otherwise LP-F parameter exhibits the compen-
satory mechanism relying on the non- lesioned (right) side.
Initial time parameter has an analogous in PD, bradykinesia.
This sign is evident in HP animals who display longer
latency times in relation to the other groups. What is more,
HP initial time in RP-F direction of movement is the highest,
meaning less response in the lesioned group. Then, estrogen
treatment improved this deficiency.
Stepping time was significantly different only in HP testing
sequence. From this result we can conclude that compen-
satory mechanisms activate to perform forelimb movement,
even though they can not restore the function in the lesioned
animal. In the case of HP+E animals such difference is not
evident, so there is a beneficial effect of estrogen that could
be improving this pathological condition.
Step length is an indicator of step power. There is a tendency
in HP+E animals to maintain the magnitude of movement
near 49px (11.27 cm). In contrast, lesioned animals who
did not receive estrogen treatment display a lower average
energy, this fact can be interpreted as another estrogen
compensatory mechanism.
To sum up, this software development and implementation
is a worthy tool to in vivo infer on forelimb akinesia in an
animal model of PD. By means of increasing the number of
motor parameters assessed, there is a better picture of how
the nigrostriatal system functions in normal and pathological
conditions. In the same way, we obtain a new sensitive
approach in the effect of estrogen as a neuroprotective
drug in PD as it restores balance, mobility, speed and also
diminishes bradykinesia.
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